Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(736) amide infused at near-physiological insulinotropic hormone and glucose concentrations
The patent for the latest GLP-1 Semaglutide is expiring in March 2026 in India and RoW and extending till 2032 in USA, which would open the opportunities for a lot of generic producing companies to enter this market
Sustained Support & Lifestyle Integration Our commitment extends beyond just medication
Orforglipron lowers the barrier to entry for the foundational GLP-1 component, making it easier for more patients to start treatment
US$ 28.15
US$ 29.92
US$ 28.35
US$ 23.02
US$ 20.95
US$ 26.59
US$ 23.88
US$ 21.81
US$ 27.44
US$ 29.69
US$ 21.52
US$ 22.18
US$ 26.44
US$ 20.36
US$ 24.33
